European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent

Taking stock of the drug industry, from the lab to the medicine chest

December 6, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent The U.S. Federal Trade Commission, however, has yet to issue its own views on the proposed acquisition, which has raised antitrust concerns. By Ed Silverman STAT+ | Inside a Nobel-winning marriage: They see each other as scientific equals, even if the prize committee doesn't Victor Ambros, Nobel Prize winner in medicine, credits crucial contributions from his wife, lab manager, and research co-author Rosalind Lee By Megan Molteni Centene cancels in-person investor's day event in wake of UnitedHealthcare CEO killing Health insurers move to virtual investor events, delete executive information from websites after shooting death of United Healthcare CEO Brian Thompson. By Annalisa Merelli

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser